Novel bifidobacterium bifidum HEM972 strain and composition for improving intestinal environment comprising same or culture thereof
Through the HEM972 strain of Bifidobacterium bifidobacterium, promotes the production of beneficial short-chain fatty acids, inhibits the production of harmful acids, solves the problem of intestinal diseases caused by imbalance in intestinal flora, and achieves improvement of the intestinal environment and prevention and treatment of various diseases.
Patent Information
- Application Number
- CN202380036781.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-28
- Filing Date
- 2023-03-30
- Publication Date
- 2024-12-06
AI Technical Summary
Modern living habits lead to imbalance intestinal flora, causing intestinal diseases such as indigestion, constipation, and colorectal cancer. The existing compositions have limited effects in improving the intestinal environment and treating diseases.
Developed Bifidobacterium bifidum HEM972 strain to promote the production of beneficial short-chain fatty acids such as butyric acid and propionic acid, and inhibit the production of harmful short-chain fatty acids such as isobutyric acid, for intestinal environmental improvement and intestinal diseases. Treatment or prevention.
It is suitable for pharmaceutical, food and feed compositions by increasing the ratio of beneficial short-chain fatty acids, improving the intestinal environment, suppressing inflammation and cancer risks, and preventing and treating a variety of intestinal diseases.
Smart Images

Figure CN119095949A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to a Bifidobacterium bifidum HEM972 strain (KCTC14144BP), a composition for improving the intestinal environment containing the same, and a composition for treating or preventing intestinal diseases. Background Art
[0002] With the bad diet and unhealthy living habits of modern people, such as meat-based diet, instant and processed food-based diet, excessive intake of stimulating foods, and hasty changes in food intake due to busy living environments, as well as the increase in age, harmful bacteria are more dominant than beneficial bacteria, thus destroying the balance of intestinal bacteria and bringing more adverse effects on intestinal health, which may induce indigestion, constipation, and colorectal cancer. Therefore, in order to prevent and improve this disease, various solutions are being studied, such as exercise therapy or the subsequent intake of health functional foods.
[0003] Gut flora (microbiota) as a microbial flora refers to the microbial colonies in the environment. It is well known that the gut flora plays an important role in maintaining the homeostasis of the host, such as human immunity, metabolic substances, etc. The gut flora transmits and receives chemical signals with the host, and the expression of immune cells or the production of neurotransmitters, short chain fatty acids (SCFA) caused by the gut flora have a huge impact on the host's system. In particular, probiotics / prebiotics balance the unbalanced gut flora in the host. Therefore, the metabolic products of healthy gut flora can promote the health of the host.
[0004] As a result of research on compositions for improving the intestinal environment, there are compositions containing a water extract of red yeast rice as an active ingredient (Korean Patent No. 10-1850308), compositions containing an ethanol extract of Adenophora radix as an active ingredient (Korean Patent No. 10-1826673), etc. However, there is still a need to develop and study compositions that exhibit excellent effects for improving the intestinal environment and treating intestinal diseases.
[0005] Therefore, as a result of intensive research to develop an excellent composition that can improve the intestinal environment and treat or prevent intestinal diseases, the inventors developed a new strain that has the ability to promote the production of beneficial short-chain fatty acids and the ability to inhibit the production of harmful short-chain fatty acids, and completed the present invention. Summary of the invention
[0006] Problems to be solved by the invention
[0007] The present application aims to provide a Bifidobacterium bifidum HEM972 strain (KCTC14144BP), a composition for improving the intestinal environment comprising the above strain, and a composition for treating or preventing intestinal diseases.
[0008] However, the technical problems to be solved by the present application are not limited to the above-mentioned technical problems, and those skilled in the art can clearly understand other technical problems not mentioned through the following description.
[0009] Solutions for solving problems
[0010] In a first aspect of the present application, a Bifidobacterium bifidum HEM972 strain (KCTC14144BP) is provided.
[0011] According to a second aspect of the present application, there is provided a food composition for improving the intestinal environment comprising Bifidobacterium bifidum HEM972 strain (KCTC14144BP) or a culture thereof as an effective ingredient.
[0012] According to a third aspect of the present application, there is provided a composition for treating or preventing intestinal diseases, comprising Bifidobacterium bifidum HEM972 strain (KCTC14144BP) or a culture thereof as an active ingredient.
[0013] Effects of the Invention
[0014] According to one embodiment of the present application, the Bifidobacterium bifidum HEM972 strain (KCTC14144BP) promotes the production of beneficial short-chain fatty acids, such as butyric acid, propionic acid, etc., and inhibits the production of harmful short-chain fatty acids, such as isobutyric acid, etc., thereby improving the intestinal environment, or treating or preventing intestinal diseases, and the above-mentioned strain can be applied to pharmaceutical compositions, food compositions, health functional food compositions, feed compositions, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 is a diagram schematically showing a method for measuring the ability to promote and reduce short-chain fatty acid production in a novel strain.
[0016] Figure 2 This is a diagram showing the results of confirming the ability of the novel strain to promote butyrate production.
[0017] Figure 3 This is a diagram showing the results of confirming the ability of the novel strain to promote propionic acid production.
[0018] Figure 4 This is a diagram showing the results of confirming the ability of the novel strain to reduce isobutyric acid production.
[0019] Figure 5 This is a diagram showing the results that the novel strain does not produce short-chain fatty acids by itself. DETAILED DESCRIPTION
[0020] Hereinafter, embodiments of the present application will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily implement the present application. However, the present application can be implemented in a variety of different forms, and the present application is not limited to the embodiments described herein. Moreover, in order to clearly illustrate the present application, parts not related to the description are omitted in the accompanying drawings, and similar parts are given similar reference numerals throughout the specification.
[0021] In the entire specification of the present application, when a certain component is located “on” other components, it not only includes the case where the certain component is connected to other components, but also includes the case where another component exists between the two components.
[0022] In the overall specification of this application, when a part "includes" a certain structural element, it means that other structural elements may also be included in the absence of special contrary records, rather than excluding other structural elements. The terms "approximately", "substantially", etc. used in the overall specification of this application are used in the sense of being equal to or close to the numerical value when presenting the manufacturing and material tolerances inherent in the said meaning, and are used to prevent unethical infringers from improperly using the disclosure of precise or absolute numerical values described to help understand the present application. The terms "~ (carry out) step" or "step of ~" used in the overall specification of this application do not mean "step for ~".
[0023] In the entire specification of this application, the term "their combination(s)" included in the expression in Markush form refers to a mixture or combination of one or more selected from the group consisting of structural elements recorded in the expression in Markush form, and refers to one or more selected from the group consisting of the above-mentioned structural elements.
[0024] In the entire specification of the present application, the description of "A and / or B" means "A or B, or A and B".
[0025] Hereinafter, embodiments and examples of the present application will be described in detail with reference to the accompanying drawings. However, the present application may not be limited to such embodiments and examples and the accompanying drawings.
[0026] In a first aspect of the present application, a Bifidobacterium bifidum HEM972 strain (KCTC14144BP) is provided.
[0027] In one embodiment of the present application, the above-mentioned strain can promote the production of beneficial short-chain fatty acids, specifically, can increase the content ratio of beneficial short-chain fatty acids in the overall short-chain fatty acid content.
[0028] In one embodiment of the present application, the above-mentioned strain can promote the production of butyric acid. Specifically, the above-mentioned strain can promote the production of butyric acid in the intestinal environment or intestinal flora.
[0029] The term "butyrate" used in the entire specification of this application is a metabolite that is beneficial to the human body and is produced by the fermentation of carbohydrates by intestinal microorganisms, and is used as an energy source for colon cells. In addition, it inhibits colon inflammation and enhances the tight junction function of colon cells, thereby playing a role in making the colon healthy and regulating immunity. Furthermore, it is well known that it has the effect of inhibiting colon cancer and preventing various intestinal diseases by affecting cell apoptosis.
[0030] Therefore, the Bifidobacterium bifidum HEM972 strain of the present application increases the ratio of butyric acid in intestinal short-chain fatty acids by promoting the production of butyric acid in the intestinal environment or intestinal flora, which can show the effects of inhibiting colon inflammation, regulating colon immunity and inhibiting colon cancer.
[0031] In one embodiment of the present application, the above-mentioned strain can promote the production of propionic acid. Specifically, the above-mentioned strain can promote the production of propionic acid in the intestinal environment or intestinal flora.
[0032] As is well known, the term "propionate (propionic acid)" used in the entire specification of this application is a normal metabolite produced by the fermentation of carbohydrates by intestinal microorganisms, which is beneficial to intestinal health, such as having anti-inflammatory and anti-cancer effects, inhibiting fat production, and helping the surface of large intestine cells and irritable bowel syndrome.
[0033] Therefore, the Bifidobacterium bifidum HEM972 strain of the present application promotes the production of propionic acid in the intestinal environment or intestinal flora, thereby increasing the ratio of propionic acid in short-chain fatty acids in the intestine. It can be seen that it can exhibit anti-inflammatory effects, anti-cancer effects, and lipogenesis inhibition effects, improve the surface of large intestinal cells, and treat or prevent irritable bowel syndrome.
[0034] In one embodiment of the present application, the above-mentioned strain can reduce the production of harmful short-chain fatty acids, specifically, can reduce the content ratio of harmful short-chain fatty acids in the overall short-chain fatty acid content.
[0035] In one embodiment of the present application, the strain can reduce the production of one or more selected from the group consisting of isobutyric acid and isovaleric acid.
[0036] In one embodiment of the present application, the above-mentioned strain can reduce the production of isobutyric acid.
[0037] As is well known, the term "isobutyrate (Isobutyric acid)" used in the entire specification of this application is a harmful metabolite produced by abnormal fermentation of intestinal microorganisms. It is found in higher concentrations in patients with various intestinal diseases, specifically, irritable bowel syndrome, ulcerative colitis, colorectal cancer, steatorrhea, Crohn's disease, Low Anterior Resection Syndrome (LARS) and Leaky Gut Syndrome, and is therefore closely related to the deterioration of intestinal health.
[0038] Therefore, the Bifidobacterium bifidum HEM972 strain of the present application reduces the ratio of isobutyric acid in intestinal short-chain fatty acids by inhibiting the production of isobutyric acid in the intestinal environment or intestinal flora, which can show the effect of treating or preventing various intestinal diseases.
[0039] In one embodiment of the present application, the above-mentioned strain may not be able to autonomously produce short-chain fatty acids. Specifically, the above-mentioned strain can promote the production of beneficial short-chain fatty acids in the intestinal environment, intestinal substances and / or intestinal flora.
[0040] In one embodiment of the present application, the above-mentioned strains can improve the intestinal environment, or treat or prevent intestinal diseases. Specifically, the above-mentioned strains can be included in various compositions such as pharmaceutical compositions for improving the intestinal environment or treating intestinal diseases, food compositions, health functional food compositions, feed compositions, etc.
[0041] The second aspect of the present application provides a food composition for improving the intestinal environment comprising Bifidobacterium bifidum HEM972 strain (KCTC14144BP) or a culture thereof as an effective ingredient. The contents repeated in the first aspect also apply to the food composition of the second aspect.
[0042] The term "improvement" used throughout the present specification refers to all actions that improve or enhance the intestinal environment by administering the above-mentioned composition.
[0043] The term "improvement of the intestinal environment" used in the entire specification of this application refers to the change of the structure of intestinal microorganisms and metabolites of the above microorganisms in a beneficial direction, or the improvement of intestinal flora, or the improvement of intestinal function and intestinal health, etc., which can increase the beneficial bacteria and metabolites of the beneficial bacteria in the intestine by improving the intestinal environment to show the effects of synthesizing vitamins, enhancing digestion and absorption, preventing infection and strengthening immunity, and reduce intestinal decay, bacterial toxins and carcinogens by reducing harmful bacteria and harmful bacteria metabolites. In addition, by improving the intestinal environment, not only can intestinal-related diseases such as diarrhea, constipation and enteritis be prevented or treated, but also cancer, obesity, diabetes and brain-related diseases can be prevented or treated.
[0044] In one embodiment of the present application, the above-mentioned improvement in the intestinal environment is selected from one or more of the group consisting of increasing the microbial diversity of intestinal flora, improving intestinal flora, enhancing beneficial intestinal bacteria, improving and enhancing intestinal health, reducing endotoxins and hydrogen sulfide derived from intestinal microorganisms, increasing metabolites derived from beneficial intestinal flora, increasing beneficial short-chain fatty acids, reducing harmful short-chain fatty acids, increasing the types and numbers of beneficial bacteria and reducing the types and numbers of harmful bacteria, but is not limited to this.
[0045] In one embodiment of the present application, the composition may be a composition for improving intestinal flora, a composition for enhancing intestinal beneficial bacteria, or a composition for improving intestinal health.
[0046] In one embodiment of the present application, the composition can promote the production of beneficial short-chain fatty acids, specifically, can promote the production of butyric acid and / or propionic acid.
[0047] In one embodiment of the present application, the composition can inhibit the production of harmful short-chain fatty acids, specifically, can inhibit the production of isobutyric acid and / or isovaleric acid, and more specifically, can inhibit the production of isobutyric acid.
[0048] In one embodiment of the present application, the above composition can promote the production of beneficial short-chain fatty acids in the intestinal environment, intestinal substances and / or intestinal flora.
[0049] In one embodiment of the present application, the above composition can treat or prevent intestinal diseases.
[0050] In one embodiment of the present application, the above-mentioned composition may include Bifidobacterium bifidum HEM972 strain, its living bacteria, its dead bacteria, its culture solution, its lysate and / or its extract.
[0051] The term "dead bacteria" used in the entire specification of this application is the opposite of live bacteria, and refers to the form in which live bacteria and metabolites obtained by fermentation cannot grow by heat treatment, etc. Dead bacteria may include antimicrobial active substances such as cytoplasm, cell wall, bacteriocin, polysaccharides, organic acids, etc. Products using the above-mentioned dead bacteria have higher stability than live bacteria products, especially excellent heat resistance, and high stability to the external environment. Therefore, compared with existing live bacteria products, they have the advantages of easy storage and extended shelf life. In addition, as the control of the use of antibiotics is being strengthened, the usability as an alternative, as well as the marketability and growth potential brought about by the fact that there are only a handful of companies that have officially invested in the production of dead bacteria products, are very large.
[0052] The term "culture liquid" used in the entire specification of the present application refers to a substance obtained by culturing the strain of the present application in a known liquid medium or solid medium, and can be used together with a "culture".
[0053] The term "food" used in the entire specification of this application includes: meat, sausage, bread, chocolate, candy, snacks, biscuits, pizza, instant noodles, other noodles, chewing gum, dairy products including ice cream, various seasonings, beverages, tea, drinks, alcoholic beverages, multivitamins, health functional foods and health foods, etc., and includes all foods in the conventional sense.
[0054] The term "health functional food" used in the entire specification of this application refers to food manufactured and processed using raw materials or ingredients with functional properties that are useful to the human body in accordance with Act No. 6727 on health functional foods. "Functionality" means the effects of health uses such as regulating nutrients or obtaining physiological effects on the structure and function of the human body.
[0055] The food of the present application can be manufactured by the conventional method used in this area, and when manufacturing the above-mentioned food, it can be manufactured by adding the raw materials and ingredients conventionally added in this area. In addition, if the dosage form of the above-mentioned food belongs to the dosage form identified as food, it can also be manufactured without restriction. The food composition of the present invention can be manufactured in the dosage form of various forms, and unlike general medicines, because food is used as raw material, it has the advantage of not producing the side effects that may be produced when taking medicine for a long time, and has excellent portability, therefore, the food of the present invention can be taken as an adjuvant for enhancing the improvement effect of the intestinal environment.
[0056] The above-mentioned health food refers to a food that has the effect of actively maintaining or enhancing health compared to general food, and a health supplement food refers to a food for the purpose of health supplement. Depending on the circumstances, the terms of health functional food, health food, and health supplement food can be mixed. Specifically, the above-mentioned health functional food is a food made by adding the Bifidobacterium bifidum HEM972 strain of the present application to food materials such as beverages, teas, spices, chewing gum, biscuits, etc., or by encapsulation, powderization, suspension, etc., which means that when it is taken, it will bring specific effects on health. Unlike general medicines, food is used as a raw material, so it has the advantage of not having side effects that may occur when taking medicines for a long time.
[0057] The food composition of the present application can be taken daily and can be expected to have a high effect in improving the intestinal environment, and therefore can be used very effectively.
[0058] The food composition may further include a physiologically acceptable carrier, but the type of the carrier is not particularly limited, and any carrier conventionally used in the technical field may be used.
[0059] In addition, the above-mentioned food composition can include additional ingredients that are commonly used in food compositions and can improve smell, taste, and vision. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folic acid, pantothenic acid, etc. can be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr) can be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine can be included.
[0060] In addition, the above-mentioned food composition may include preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder and high-efficiency bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), color developers (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, sodium cyclamate, saccharin, sodium, etc.), spices (vanillin, lactones, etc.), expanders (alum, D-potassium hydrogen tartrate, etc.), enhancers, emulsifiers, tackifiers (paste), film-forming agents, gum bases, defoamers, solvents, improvers, and other food additives. The above-mentioned additives can be screened according to the type of food and used in an appropriate amount.
[0061] The Bifidobacterium bifidum HEM972 strain of the present application can be directly added or used together with other foods or food ingredients, and can be appropriately used according to conventional methods. The mixing amount of the active ingredient can be appropriately determined according to its purpose of use (prevention, health care or therapeutic treatment). Usually, in the case of manufacturing food or beverages, the food composition of the present invention can be added to food or beverages in an amount of less than 50 parts by weight, specifically, less than 20 parts by weight. However, when taken for a long time for the purpose of health care and hygiene, the content below the above range can be included, and there is no problem in terms of safety, so the active ingredient can also be used in an amount above the above range.
[0062] As an example of the food composition of the present application, it can be used as a health drink composition. In this case, like conventional beverages, various flavoring agents or natural carbohydrates can be included as additional ingredients. The above-mentioned natural carbohydrates can be monosaccharides, such as glucose and fructose; disaccharides, such as maltose and sucrose; polysaccharides, such as dextrin and cyclodextrin; sugar alcohols, such as xylitol, sorbitol, erythritol, etc. For sweeteners, natural sweeteners such as thaumatin and stevia extract can be used; synthetic sweeteners such as saccharin and aspartame; etc. In each 100 mL of the health drink composition of the present invention, the ratio of the above-mentioned natural carbohydrates can generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g.
[0063] In addition to the above, the health drink composition can include various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectin acid, pectate, alginic acid, alginate, organic acid, protective colloid thickener, pH regulator, stabilizer, preservative, glycerol, alcohol or carbonating agent, etc. In addition, it can include pulp for making natural fruit juice, fruit juice drink or vegetable drink. This ingredient can be used alone or in combination. Although the ratio of this additive is not very important, the selection range of the above additive is usually 0.01 to 0.1 weight part relative to every 100 weight parts of the health drink composition of the present invention.
[0064] If the food composition of the present application can show an effect of improving the intestinal environment, the Bifidobacterium bifidum HEM972 strain of the present application can be included in various weight %; specifically, relative to the total weight of the food composition, it can include 0.00001 to 100 weight % or 0.01 to 80 weight % of the Bifidobacterium bifidum HEM972 strain of the present application, but is not limited thereto.
[0065] In one embodiment of the present application, the food composition may be a health functional food composition.
[0066] The third aspect of the present application provides a composition for treating or preventing intestinal diseases comprising Bifidobacterium bifidum HEM972 strain (KCTC14144BP) or a culture thereof as an effective ingredient. The contents repeated in the first and second aspects also apply to the pharmaceutical composition of the third aspect.
[0067] In one embodiment of the present application, the above-mentioned composition may include Bifidobacterium bifidum HEM972 strain, its living bacteria, its dead bacteria, its culture solution, its lysate and / or its extract.
[0068] The term "intestinal disease" used in the entire specification of this application refers to all diseases caused or may be caused by the deterioration of the intestinal environment, imbalance of intestinal bacteria (intestinal flora), deterioration of intestinal health, intestinal damage, etc., and may include intestinal damage, stomach diseases, digestive organ diseases, digestive organ damage, etc.
[0069] In one embodiment of the present application, the above-mentioned intestinal disease can be one or more selected from the group consisting of inflammatory bowel disease, irritable bowel syndrome (IBS), ulcerative colitis (UC), colorectal cancer, steatorrhea (Celiac disease), Crohn's disease (Crohn's disease), Low Anterior Resection Syndrome (LARS) and leaky gut syndrome, but if it is a disease caused by abnormal intestinal state, etc., it is not limited to this.
[0070] The term "treatment" used in the entire specification of the present application refers to all actions of administering a pharmaceutical composition comprising the Bifidobacterium bifidum HEM972 strain of the present application as an active ingredient to an individual suffering from an intestinal disease to improve or ameliorate the symptoms of the intestinal disease.
[0071] In one embodiment of the present application, the composition can promote the production of beneficial short-chain fatty acids, specifically, can promote the production of butyric acid and / or propionic acid.
[0072] In one embodiment of the present application, the composition can inhibit the production of harmful short-chain fatty acids, specifically, can inhibit the production of isobutyric acid and / or isovaleric acid, and more specifically, can inhibit the production of isobutyric acid.
[0073] In one embodiment of the present application, the above composition can promote the production of beneficial short-chain fatty acids in the intestinal environment, intestinal substances and / or intestinal flora.
[0074] In one embodiment of the present application, the composition can improve the intestinal environment.
[0075] In one embodiment of the present application, the above-mentioned pharmaceutical composition can be formulated and used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and other oral dosage forms; external medicines; suppositories and sterile injection solutions according to conventional methods, but are not limited thereto.
[0076] In one embodiment of the present application, when the pharmaceutical composition is formulated, it can be prepared by using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants or surfactants, but is not limited thereto.
[0077] In one embodiment of the present application, the solid preparation for oral administration may include tablets, pills, powders, granules or capsules, etc., and such solid preparations may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose or gelatin, with the dead cells of the above-mentioned strains. In addition, for example, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used, but are not limited thereto.
[0078] In one embodiment of the present application, liquid preparations for oral administration include suspensions, oral solutions, emulsions, syrups, etc., and in addition to water and liquid paraffin as commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included, but not limited to these.
[0079] In one embodiment of the present application, the preparation for parenteral administration may include a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation and a suppository, but not limited thereto. For example, as the above-mentioned non-aqueous solvent or suspension, vegetable oils such as propylene glycol, polyethylene glycol, olive oil; injectable esters such as ethyl oleate, etc. may be used, but not limited thereto. For example, as the above-mentioned suppository, semi-synthetic fatty acid esters (witepsol), polyethylene glycol, Tween 61, cocoa butter, lauric acid glyceride, glyceryl gelatin, etc. may be used, but not limited thereto.
[0080] The pharmaceutical composition according to one embodiment of the present application may be a drug composition or a quasi-drug composition.
[0081] The term "quasi-drug" used in the entire specification of this application refers to an item used for the purpose of diagnosing, treating, ameliorating, alleviating, treating or preventing diseases in humans or animals, and its effect is milder than that of drugs. For example, according to the provisions of the Pharmacists Act, quasi-drugs refer to items other than items used as drugs, and include products used to treat or prevent diseases in humans and animals, products that have little effect on the human body or do not directly act on the human body, etc.
[0082] The above-mentioned quasi-drug composition of the present application can be manufactured into a dosage form selected from the group consisting of body cleansers, disinfecting cleansers, cleaning agents, kitchen cleansers, cleaning cleansers, toothpastes, mouthwashes, wet wipes, detergents, soaps, hand soaps, hair cleansers, hair softeners, humidifier fillers, masks, ointments, and filter fillers, but is not limited thereto.
[0083] In one embodiment of the present application, the above-mentioned pharmaceutical composition can be administered in a pharmaceutically effective amount, and the term "pharmaceutically effective amount" of the present application refers to an amount that is applicable to medical treatment or prevention and is sufficient to treat or prevent a disease at a reasonable benefit / risk ratio. For the effective dose level, it can be determined based on factors including the severity of the disease, the activity of the drug, the age, weight, health, sex, sensitivity of the patient to the drug, the administration time, route of administration, and excretion rate treatment cycle of the composition of the present invention used, the elements of the drug used in conjunction with or together with the composition of the present invention used, and other well-known elements in the medical field. The pharmaceutical composition of the present application can be administered alone or in combination with components known to show therapeutic effects on intestinal diseases. It is important to administer the amount that achieves the maximum effect and has no side effects by considering all the above elements.
[0084] In one embodiment of the present application, for the dosage of the above-mentioned pharmaceutical composition, those skilled in the art may determine it by considering the purpose of use, the severity of the disease, the patient's age, weight, sex, past history, or the type of substance used as an active ingredient. For example, the pharmaceutical composition of the present invention can be administered in an amount of about 0.1 ng to about 1000 mg / kg per adult, preferably about 1 ng to about 100 mg / kg, and the frequency of administration of the composition of the present application is not limited thereto, but can be administered once a day, or by splitting the doses and administering them multiple times. The above dosage or number of administrations does not limit the scope of the present application at any level.
[0085] The fourth aspect of the present application provides a method for treating intestinal diseases, comprising the step of administering the above-mentioned pharmaceutical composition of the present application in a pharmaceutically effective amount to an individual suffering from intestinal diseases. The contents repeated in the first to third aspects also apply to the method of the fourth aspect.
[0086] The term "individual" used in the entire specification of this application may include, but is not limited to, mammals including mice, livestock, humans, etc., who suffer from intestinal diseases or are at risk of suffering from intestinal diseases; farmed fish, etc.
[0087] In one embodiment of the present application, the above-mentioned individuals may not include humans.
[0088] In one embodiment of the present application, the pharmaceutical composition can be administered in a single or multiple doses in a pharmaceutically effective amount. In this case, the composition can be formulated and administered in the form of a liquid, powder, aerosol, injection, infusion (Ringer's), capsule, pill, tablet, suppository or patch.
[0089] Regarding the administration route of the pharmaceutical composition for preventing or treating intestinal diseases of the present application, it can be administered through any conventional route as long as it can reach the target tissue.
[0090] The pharmaceutical composition of the present application is not particularly limited thereto, but can be administered by intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, transdermal patch administration, oral administration, intranasal administration, intrapulmonary administration, rectal administration and other routes according to the purpose. However, when administered orally, it can also be administered in an unformulated form, and since the above-mentioned Bifidobacterium bifidum HEM972 strain may be denatured or decomposed by gastric acid, the oral composition can be applied to the oral cavity in the form of a formulation or oral patch that is coated with an active agent or protects it from decomposition in the stomach. In addition, the above-mentioned composition can be administered by any device that can move the active substance to the target cell.
[0091] Embodiments of the present invention
[0092] Hereinafter, the present invention will be described in more detail through the examples of the present application, but the following examples are only used to help understand the present application, and the content of the present application is not limited to the following examples.
[0093] [Example]
[0094] Example 1: Confirmation of the ability of Bifidobacterium bifidum HEM972 to promote the production and reduction of short-chain fatty acids
[0095] In order to confirm the ability of Bifidobacterium bifidum HEM972 (Bifidobacterium bifidum HEM972, depository institution: Korea Type Culture Collection, deposit number: KCTC14144BP, deposit date: February 21, 2020), which is a novel strain of the present application, to promote the production and reduction of short-chain fatty acids, the following experiment was conducted.
[0096] Example 1-1: In vitro conditional culture for analysis of short-chain fatty acid production
[0097] In order to confirm the production amount of short-chain fatty acids by the strain according to the present application under in vitro conditions, the strain was cultured by the following method.
[0098] First, an intestinal environment-similar culture medium with the following composition was prepared, and then replaced in an anaerobic box (Whitley A95 anaerobic workstation) for 24 hours to make the culture medium in an anaerobic state.
[0099] -Intestinal environment similar culture medium: NaCl 60mM, NaHCO3 40mM, KCl 10mM, Hemin5×10 -5 g / L, mucin 0.5% (w / v), L-cysteine HCl 0.05% (w / v)
[0100] In each well of a 96-well plate, the inoculation concentration of the experimental group (HEM972, PB_B) was 5×107 The corresponding strain with CFU / ml was 30ul, intestinal environment-similar culture medium was 180ul, and human fecal sample was 15mg. The wells of the untreated control group (NC, negative control) were inoculated with intestinal environment-similar culture medium 210ul and human fecal sample 15mg. In addition, in order to use PB_B as a reference, a bifidobacterium strain of the same genus as the commercialized probiotics was used. The experimental group strain HEM972 refers to Bifidobacterium bifidum HEM972.
[0101] Next, the 96-well plate inoculated with the above experimental group and control group was cultured in an anaerobic chamber (whitley A95 anaerobic workstation) with stirring using a stirrer (DLAB mx-m) for 18 hours, and after culture, centrifuged at 3800 rpm for 10 minutes, and 100ul of the supernatant of each well was transferred to a 96-well cell culture plate. Next, 100ul of GC extraction solution for extracting metabolites [GC extraction solution ingredients: DW 10ml, NaCl 3.3g, phosphoric acid (Phosphoric acid) 50ul, 2-ethyl butyric acid (2-ethyl butyric acid) 0.5ul] and DW 50ul and the supernatant of the above 96-well cell culture plate were inoculated into 96 GC (gas chromatography) vials in an amount of 50ul each, and acetic acid, propionic acid, butyric acid and isobutyric acid as microbial metabolites were analyzed using gas chromatography (gas chromatography) analysis method ( Figure 1 ).
[0102] Example 1-2: Confirmation of the ability to promote butyrate production
[0103] The change in the butyric acid ratio according to the treatment with the novel strain was confirmed by the gas chromatography analysis method performed in the above Example 1-1. Specifically, the butyric acid ratio can be confirmed as the ratio of butyric acid to the total amount of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid, which are normal short-chain fatty acids present in one sample.
[0104] Figure 2"Total SCFA" means the total amount of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid, "Butyrate" means the amount of butyric acid, and "Butyrate / Total SCFA" is the value of the amount of butyric acid divided by "Total SCFA", which indicates the ratio of butyric acid. In order to easily confirm the increase or decrease of butyric acid in each experimental group as a case of treating bacteria compared with the control group (NC) where no bacteria were treated, the Butyrate / Total SCFA value of NC was expressed as 100%, and the Butyrate / Total SCFA of each experimental group (TG) was divided by the TG / NC value of NC to express the above increase or decrease. In addition, to compare the butyrate / total SCFA values of each experimental group and the control group (NC), statistical significance was confirmed by one-way ANOVA (post hoc test: Fisher's LSD) for NC and HEM972, respectively, and marked with * (P value < 0.05), ** (P value < 0.01), *** (P value < 0.001) in the bar graph, and to compare the butyrate / total SCFA values of HEM972 and PB_B as a reference strain, statistical significance was confirmed by one-way ANOVA (post hoc test: Fisher's LSD) and marked with # (P value < 0.05), ## (P value < 0.01), ### (P value < 0.001).
[0105] The above results of butyrate increase and decrease were confirmed, and it was confirmed that the butyrate ratio was statistically significantly increased in the case of HEM972 strain treatment compared with the control group and PB_B ( Figure 2 ).
[0106] Based on the above results, it can be seen that the HEM972 strain of the present application has the function of promoting butyrate production in the intestinal environment (intestinal flora).
[0107] Example 1-3: Confirmation of the ability to promote propionate production
[0108] The gas chromatography analysis method performed in Example 1-1 above confirmed the change in the propionic acid ratio according to the treatment with the novel strain. Specifically, the propionic acid ratio can be confirmed as the ratio of propionic acid to the total amount of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid, which are normal short-chain fatty acids present in one sample.
[0109] Figure 3In the table, "total SCFA" refers to the total amount of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid, "propionate" refers to the amount of propionic acid, and "propionate / total SCFA" is the value of the amount of propionic acid divided by "total SCFA", indicating the ratio of propionic acid. In order to easily confirm the increase or decrease of propionic acid in each experimental group as a case of treating bacteria compared with the control group (NC) in which no bacteria were treated, the propionate / total SCFA value of NC was expressed as 100%, and the increase or decrease was expressed by dividing the propionate / total SCFA of each experimental group (TG) by the TG / NC value of NC. In addition, to compare the butyrate / total SCFA values of each experimental group and the control group (NC), statistical significance was confirmed by one-way ANOVA (post hoc test: Fisher's LSD) for NC and HEM972, respectively, and marked with * (P value < 0.05), ** (P value < 0.01), *** (P value < 0.001) in the bar graph, and to compare the butyrate / total SCFA values of HEM972 and PB_B as a reference strain, statistical significance was confirmed by one-way ANOVA (post hoc test: Fisher's LSD) and marked with # (P value < 0.05), ## (P value < 0.01), ### (P value < 0.001).
[0110] The above results of propionic acid increase and decrease were confirmed, and it was confirmed that the propionic acid ratio was statistically significantly increased in the case of HEM972 strain treatment compared with the control group and PB-B ( Figure 3 ).
[0111] Based on the above results, it can be seen that the HEM972 strain of the present application has the function of promoting the production of propionic acid in the intestinal environment (intestinal flora).
[0112] Example 1-4: Confirmation of the ability to reduce the production of isobutyrate
[0113] The change in the isobutyric acid ratio due to the treatment with the novel strain was confirmed by the gas chromatography analysis method performed in Example 1-1.
[0114] Figure 4Here, "isobutyrate" refers to the amount of isobutyric acid. In order to easily confirm the increase or decrease of isobutyric acid in each experimental group under the condition of treated bacteria compared with the control group (NC) without any bacteria treatment, the isobutyrate value of NC is expressed as 100%, and the increase or decrease is expressed by dividing the isobutyrate value of each experimental group (TG) by the TG / NC value of NC. In addition, to compare the isobutyrate values of HEM972 and the control group (NC), statistical significance was confirmed for NC and the experimental group by one-way ANOVA (post hoc test: Fisher's LSD) and marked with * (P value < 0.05), ** (P value < 0.01), *** (P value < 0.001) in the bar graph, and to compare the isobutyrate values of HEM972 and PB_B as a reference strain, statistical significance was confirmed by one-way ANOVA (post hoc test: Fisher's LSD) and marked with # (P value < 0.05), ## (P value < 0.01), ### (P value < 0.001).
[0115] The above results of isobutyric acid increase and decrease were confirmed, and it was confirmed that the amount of isobutyric acid was statistically significantly reduced in the case of HEM972 strain treatment compared with the control group and PB_B ( Figure 4 ).
[0116] Based on the above results, it can be seen that the HEM972 strain of the present application has the function of inhibiting the production of isobutyric acid in the intestinal environment (intestinal flora).
[0117] Example 2: Confirmation of whether Bifidobacterium bifidum HEM972 produces short-chain fatty acids
[0118] In the above Example 1, it was confirmed that Bifidobacterium bifidum HEM972, which is a novel strain of the present application, increases the ratio of butyric acid to propionic acid and inhibits the production of isobutyric acid. However, the above experiment did not clearly indicate whether the strain itself produces butyric acid and propionic acid, and whether the strain promotes the production of the above short-chain fatty acids in the intestinal environment. In order to clarify this point, the following experiment was conducted.
[0119] First, an intestinal environment-similar culture medium with the following composition was prepared, and then replaced in an anaerobic chamber (Whitley A95 anaerobic workstation) for 24 hours to make the culture medium in an anaerobic state.
[0120] -Intestinal environment similar culture medium: NaCl 60mM, NaHCO3 40mM, KCl 10mM, Hemin5×10 -5 g / L, mucin 0.5% (w / v), L-cysteine HCl 0.05% (w / v)
[0121] Next, in a 96-well plate, the experimental group A (treatment group: HEM972) was inoculated with a concentration equivalent to 5×10 7 CFU / ml of the strain 30ul, intestinal environment similar medium 195ul, inoculated in experimental group B (treatment group: HEM972) equivalent to a concentration of 5×10 7 30ul of strains with CFU / ml, 180ul of intestinal environment-similar culture medium, and 15mg of human feces sample were inoculated. In addition, 225ul of intestinal environment-similar culture medium was inoculated in the negative control (NC) wells of the untreated strains.
[0122] Next, the 96-well plate inoculated with the above experimental groups was cultured in an anaerobic chamber (Whitley A95 anaerobic workstation) using a stirrer (DLAB mx-m) for 18 hours, and after culture, it was centrifuged at 3800 rpm for 10 minutes, and 100 ul of the supernatant from each well was transferred to a 96-well cell culture plate. Next, 100ul of GC extraction solution for extracting metabolites [GC extraction solution ingredients: DW 10ml, NaCl 3.3g, phosphoric acid 50ul, 2-ethyl butyric acid 0.5ul], DW 50ul, and the supernatant of the above-mentioned 96-well cell culture plate were inoculated into 96 GC (gas chromatography) vials at 50ul each, and the production amounts of acetic acid, propionic acid, butyric acid, isobutyric acid as microbial metabolites and 2-ethyl butyric acid as GC internal standard were analyzed using gas chromatography.
[0123] The above analysis results confirmed that in experimental group A, which was treated with only the HEM972 strain but not the fecal sample, no butyric acid and propionic acid were produced, while in experimental group B, which was treated with the above strain and fecal sample, butyric acid and propionic acid were produced ( Figure 5 ).
[0124] Based on the above experimental results, it can be seen that the HEM972 strain of the present application does not have the ability to produce butyric acid and propionic acid itself, and the above strain has the function of promoting the production of butyric acid and propionic acid by stimulating and regulating intestinal flora (fecal samples).
[0125] The above description of the present application is exemplary, and those skilled in the art of the present application can understand that it can be easily transformed into other specific forms without changing the technical ideas or necessary technical features of the present application. Therefore, it should be understood that the above-described embodiments are exemplary in all aspects and not restrictive. For example, each structural element described as a single type can also be implemented in a decentralized manner. Similarly, the structural elements described as decentralized forms can be implemented in a combined form.
[0126] The scope of the present application is determined by the claims rather than the detailed description above, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present application.
[0127] [Accession number]
[0128] Depository: Korea Type Culture Collection
[0129] Accession number: KCTC14144BP
[0130] Collection date: 20200221
[0131]
Claims
1. A Bifidobacterium bifidum HEM972 strain (KCTC14144BP).
2. The strain according to claim 1, wherein The strain promotes the production of one or more selected from the group consisting of butyrate and propionate.
3. The strain according to claim 1, wherein The strain reduces the production of isobutyric acid.
4. The strain according to claim 1, wherein The strain is unable to produce short-chain fatty acids itself.
5. A food composition for improving the intestinal environment, comprising Bifidobacterium bifidum HEM972 strain (KCTC14144BP) or a culture thereof as an active ingredient.
6. A pharmaceutical composition for treating or preventing intestinal diseases, comprising Bifidobacterium bifidum HEM972 strain (KCTC14144BP) or a culture thereof as an active ingredient.
Citation Information
Patent Citations
Composition for improving intestinal health containing Codonopsis lanceolata
KR101826673B1
Composition for improving intestinal health comprising red yeast rice
KR101850308B1
